Study guide
7.3 Bronchial Provocation Testing: Methacholine Challenge, Exercise-Induced Bronchospasm, and EIB Protocols
Certified Pulmonary Function Technologist CPFT
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Overview & NBRC Certification Requirements
1.1 NBRC PFT Exam Logistics, Format, and Scoring Criteria 1.2 Scope of Practice, Candidate Admission Pathways, and Credential Maintenance 1.3 Professional Standards, Ethics, and Patient Safety in Diagnostic Testing
2 Chapter 2: Spirometry Equipment & Sensors
2.1 Volume-Displacement Spirometers: Water-Seal, Rolling-Seal, Bellows 2.2 Flow-Sensing Pneumotachometers: Fleisch, Lilly, Vortex, Turbine, Pitot Tube, Ultrasonic 2.3 Calibration Standards & 3-Liter Syringe Quality Control Verification
3 Chapter 3: Body Plethysmography & Hardware
3.1 Body Plethysmograph Principles: Pressure, Volume, and Variable-Pressure-Constant-Volume Design 3.2 Plethysmograph Calibration, Pressure Transducers, and Shutter Mechanics 3.3 Quality Control, Isothermal Corrections, and Leak Detection in Plethysmography
4 Chapter 4: Gas Analyzers, Environmental Sensors, & Infection Control
4.1 Rapid and Multi-Gas Analyzers: Infrared, Zirconium, Mass Spec, Electrochemical, Thermal Conductivity 4.2 Environmental Sensors, Barometric Pressure, Temperature, and BTPS Correction Factors 4.3 Infection Control, Equipment Decontamination, Disposable Filters, and Spaulding Classification 4.4 Monitors: Pulse Oximeters, Blood Pressure Devices, and ECG Equipment 4.5 Gas Delivery Systems, Valves, Absorbers, and Aerosol / Inhaler Devices
5 Chapter 5: Spirometry Protocols & ATS/ERS Criteria
5.1 Forced Vital Capacity (FVC) and Slow Vital Capacity (SVC) Testing Protocols 5.2 ATS/ERS Spirometry Acceptability, Repeatability, and Usability Criteria 5.3 Peak Expiratory Flow Rate (PEFR), Maximum Voluntary Ventilation (MVV), and Flow-Volume Loops
6 Chapter 6: Lung Volume Determination Protocols
6.1 Open-Circuit Nitrogen Washout Method: Principles, Equipment, and Calculation 6.2 Closed-Circuit Helium Dilution Method: Principles, Equipment, and Calculation 6.3 Thoracic Gas Volume (TGV/FRCpleth) and Comparison of Lung Volume Methods
7 Chapter 7: Diffusing Capacity & Bronchial Challenge Testing
7.1 Single-Breath Carbon Monoxide Diffusing Capacity (DLCO) Testing Protocol 7.2 DLCO Calculations, Hemoglobin/COHb/Altitude Corrections, and VA 7.3 Bronchial Provocation Testing: Methacholine Challenge, Exercise-Induced Bronchospasm, and EIB Protocols 7.4 Inhaled Medication Delivery Technique and Patient Education
8 Chapter 8: Cardiopulmonary Exercise & ABG Testing
8.1 Cardiopulmonary Exercise Testing (CPET) Protocols, VO2max, and Anaerobic Threshold 8.2 Six-Minute Walk Test (6MWT) Protocol, Desaturation Monitoring, and O2 Titration 8.3 Arterial Blood Gas (ABG) Sampling, Allen Test, Analyzer Maintenance, and Quality Control 8.4 Pulse Oximetry and Oxygen Assessment: Principles, Limitations, and Titration Data 8.5 CO-Oximetry / Hemoximetry: Measurement, Dyshemoglobins, and Clinical Implications 8.6 Exercise Monitoring Data: Blood Pressure Response and ECG Rhythm Analysis
9 Chapter 9: Reference Values & PFT Calculations
9.1 Predicted Value Equations, Reference Populations, and GLI 2012 / ATS/ERS 2022 Standards 9.2 BTPS, STPD, and ATPS Conversion Formulas and Calculations 9.3 Gas Exchange Formulas, Alveolar Air Equation, and Mechanical Calculations
10 Chapter 10: Pattern Recognition & Clinical PFT Interpretation
10.1 Obstructive Ventilatory Defects: Asthma, COPD, Emphysema, Chronic Bronchitis, Bronchiectasis 10.2 Restrictive Ventilatory Defects: Parenchymal, Chest Wall, and Neuromuscular Disorders 10.3 Mixed Ventilatory Defects, Isolated Diffusion Defects, and Reversibility Protocols
11 Chapter 11: Artifact Recognition & Quality Assurance
11.1 Spirometry Artifacts: Hesitation, Coughing, Early Termination, Glottic Closure, Leak 11.2 Lung Volume and DLCO Artifacts: Panting Frequency, Shutter Leaks, Breath-Hold Failure 11.3 Quality Control Charts, Westgard Rules, and Laboratory Quality Assurance
12 Chapter 12: Documentation, Compliance, & Emergency Safety
12.1 PFT Reporting Standards, Tabular Formats, and Interpretation Graphics 12.2 CPT Billing Codes, ICD-10 Coding, HIPAA Privacy, and EHR Compliance 12.3 Emergency Preparedness, Contraindications, and Patient Safety Management in PFT Lab
13 Chapter 13: Specialized Procedures, Home Testing & Longitudinal Data
13.1 Respiratory Muscle Strength: MIP, MEP, SNIP, and Cough Peak Flow 13.2 Sputum Sample Collection: Spontaneous and Induced Specimens 13.3 Home Testing Instruction: Home Spirometry, Peak Flow Diaries, and Home Oximetry 13.4 Pediatric Pulmonary Function Testing and Upright Versus Supine Spirometry 13.5 Serial Pulmonary Function Testing, Clinical History, Demographics, and Laboratory Quality Management
7.3 Bronchial Provocation Testing: Methacholine Challenge, Exercise-Induced Bronchospasm, and EIB Protocols
Key Takeaways Explain This Topic AI
Bronchial provocation testing evaluates airway hyperresponsiveness (AHR) in patients with suspected asthma who present with normal baseline spirometry.
Methacholine (a synthetic cholinergic agonist) challenge testing uses either a 2-minute tidal breathing method or a 5-breath dosimeter method, administering serial doubling or quadrupling concentrations (typically 0.03 to 16 mg/mL).
A positive methacholine challenge is a fall in FEV1 of at least 20% from the post-diluent baseline, reported as PC20 (concentration) or, per the 2017 ERS standard, as PD20 with a normal cut-off above 400 micrograms cumulative dose.
Exercise-induced bronchospasm (EIB) testing requires achieving a target heart rate of 80% to 90% of age-predicted maximum (or minute ventilation >= 50-60% MVV) for 6 to 8 minutes while breathing dry air; a >= 10% to 15% drop in FEV1 post-exercise indicates EIB.
Patient safety requires baseline FEV1 >= 60% predicted (or > 1.5 L), immediate availability of short-acting beta-agonists (e.g., albuterol), emergency resuscitation equipment, and direct physician availability.
Last updated: August 2026
7.3 Bronchial Provocation Testing: Methacholine Challenge, Exercise-Induced Bronchospasm, and EIB Protocols
Bronchial provocation testing (also known as bronchial challenge or airway reactivity testing) is indicated to evaluate patients who present with clinical symptoms suggestive of asthma—such as chronic cough, wheezing, or exertional dyspnea—but who exhibit normal baseline resting spirometry and non-diagnostic bronchodilator reversibility testing. Bronchial challenges measure Airway Hyperresponsiveness (AHR) , characterized by exaggerated bronchoconstriction in response to pharmacological or physical stimuli.
Stimuli are broadly categorized into Direct Challenges (e.g., Methacholine, Histamine) which act directly on airway smooth muscle receptors, and Indirect Challenges (e.g., Exercise, Eucapnic Voluntary Hyperpnea [EVH], Mannitol, Hypertonic Saline) which trigger endogenous inflammatory mediator release (histamine, leukotrienes, prostaglandins) from mast cells, basophils, and airway sensory nerves.
Contraindications and Pre-Test Safety Screening
Because bronchial provocation testing deliberately induces airway constriction, rigorous pre-test safety screening is mandatory.
Absolute Contraindications
Severe Airflow Limitation: Baseline F E V 1 < 50 % to 60 % FEV_1 < 50\% \text{ to } 60\% FE V 1 < 50% to 60% of predicted (or absolute F E V 1 < 1.5 Liters FEV_1 < 1.5\text{ Liters} FE V 1 < 1.5 Liters in adults). Inducing further bronchospasm in severely obstructed patients poses life-threatening risks.
Recent Cardiovascular Events: Myocardial infarction or cerebrovascular accident (stroke) within the preceding 3 months .
Known Vascular Aneurysms: Known aortic, cerebral, or thoracic arterial aneurysm (forced exhalation and bronchospasm increase blood pressure and wall stress).
Uncontrolled Systemic Hypertension: Systolic B P > 200 mmHg BP > 200\text{ mmHg} BP > 200 mmHg or Diastolic B P > 100 mmHg BP > 100\text{ mmHg} BP > 100 mmHg .
Recent Intraocular or Thoracic Surgery: Recent eye surgery (cataract removal) or thoracic/abdominal surgery where spikes in intrathoracic/intraocular pressure are hazardous.
Pre-Test Medication Withholding Intervals
To prevent false-negative challenge results, bronchoactive medications and dietary agents must be withheld for specific time windows prior to testing:
- Medication / Substance Class Representative Examples Minimum Withholding Period
- Short-Acting Beta-Agonists (SABA) Albuterol, Levalbuterol 8 hours
- Short-Acting Anticholinergics (SAMA) Ipratropium bromide 24 hours
- Long-Acting Beta-Agonists (LABA) Salmeterol, Formoterol 36 to 48 hours
- Ultra-Long-Acting Beta-Agonists Vilanterol, Indacaterol 48 hours
- Long-Acting Anticholinergics (LAMA) Tiotropium, Umeclidinium 48 to 72 hours
- Oral Theophylline (Long-Acting) Uniphyl, Theo-24 36 to 48 hours
- Leukotriene Receptor Antagonists Montelukast, Zafirlukast 24 hours (for indirect challenges)
- Dietary Methylxanthines Coffee, tea, cola, chocolate, energy drinks 6 hours
- Methacholine Challenge Testing Protocols
Methacholine chloride is a synthetic analog of acetylcholine that binds directly to post-ganglionic muscarinic ( M 3 M_3 M 3 ) receptors on airway smooth muscle cells, triggering muscle contraction and airway narrowing.
Testing Methodologies: Tidal Breathing vs. Dosimeter
Two standardized administration techniques are endorsed by ATS/ERS guidelines:
2-Minute Tidal Breathing Method (Wright Nebulizer): The patient breathes aerosolized methacholine normally (tidal breathing) from a continuous jet nebulizer for 2.0 minutes per concentration step.
5-Breath Dosimeter Method: A breath-actuated dosimeter delivers aerosolized methacholine only during inspiration. The patient takes 5 deep, slow inspirations (from FRC to TLC with a 2-to-5 second breath-hold at TLC per breath) for each concentration step.
Step-by-Step Methacholine Challenge Sequence
Baseline Spirometry: Perform repeatable baseline spirometry. If baseline F E V 1 < 60 % FEV_1 < 60\% FE V 1 < 60% predicted, abort the test.
Diluent Control Phase: Administer the aerosolized diluent control ( 0.9 % 0.9\% 0.9% Normal Saline without methacholine). Perform spirometry at 30 seconds and 90 seconds post-inhalation.
The highest F E V 1 FEV_1 FE V 1 achieved post-diluent serves as the true control baseline for calculating the 20% decline threshold.
Control Rule: If the diluent causes a ≥ 20 % \ge 20\% ≥ 20% drop in F E V 1 FEV_1 FE V 1 relative to initial baseline, the patient is hyperreactive to the saline vehicle or nebulizer maneuver, and the test is terminated.
Serial Concentration Administration: Administer increasing concentrations of methacholine in serial doubling (e.g., 0.0625 , 0.125 , 0.25 , 0.5 , 1.0 , 2.0 , 4.0 , 8.0 , 16.0 mg/mL 0.0625, 0.125, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0\text{ mg/mL} 0.0625 , 0.125 , 0.25 , 0.5 , 1.0 , 2.0 , 4.0 , 8.0 , 16.0 mg/mL ) or quadrupling steps.
Post-Dose Spirometry: Perform acceptable F E V 1 FEV_1 FE V 1 maneuvers at 30 seconds and 90 seconds following completion of each dose step.
Termination Criteria: The challenge sequence continues until:
F E V 1 FEV_1 FE V 1 decreases by ≥ 20 % \ge 20\% ≥ 20% from the post-diluent baseline F E V 1 FEV_1 FE V 1 , OR
The maximum methacholine concentration ( 16.0 mg/mL 16.0\text{ mg/mL} 16.0 mg/mL or 25.0 mg/mL 25.0\text{ mg/mL} 25.0 mg/mL ) is reached without a 20% drop.
PC20 and PD20 Calculation and Clinical Interpretation
The primary diagnostic metric derived from a methacholine challenge is the P C 20 PC_{20} P C 20 (Provocative Concentration causing a 20% drop in F E V 1 FEV_1 FE V 1 ) or P D 20 PD_{20} P D 20 (Provocative Dose).
Calculation of P C 20 PC_{20} P C 20 via Log-Linear Interpolation
When the final dose causes an F E V 1 FEV_1 FE V 1 drop exceeding 20%, P C 20 PC_{20} P C 20 is calculated by logarithmic interpolation between the second-to-last concentration ( C 1 C_1 C 1 , causing < 20 % < 20\% < 20% drop R 1 R_1 R 1 ) and the final concentration ( C 2 C_2 C 2 , causing > 20 % > 20\% > 20% drop R 2 R_2 R 2 ): P C 20 = antilog [ log ( C 1 ) + ( log ( C 2 ) − log ( C 1 ) ) × ( 20 − R 1 ) R 2 − R 1 ] PC_{20} = \text{antilog} \left[ \log(C_1) + \frac{(\log(C_2) - \log(C_1)) \times (20 - R_1)}{R_2 - R_1} \right] P C 20 = antilog [ lo g ( C 1 ) + R 2 − R 1 ( lo g ( C 2 ) − lo g ( C 1 )) × ( 20 − R 1 ) ]
Where:
C 1 C_1 C 1 : Second-to-last methacholine concentration ( m g / m L mg/mL m g / m L ).
C 2 C_2 C 2 : Final methacholine concentration ( m g / m L mg/mL m g / m L ).
R 1 R_1 R 1 : Percent decline in F E V 1 FEV_1 FE V 1 at C 1 C_1 C 1 .
R 2 R_2 R 2 : Percent decline in F E V 1 FEV_1 FE V 1 at C 2 C_2 C 2 .
PD20: The Metric the 2017 ERS Standard Prefers
The 2017 ERS technical standard on bronchial challenge testing shifted the primary reported metric from P C 20 PC_{20} P C 20 (a concentration ) to P D 20 PD_{20} P D 20 — the cumulative dose of methacholine, in micrograms, that produces the 20% fall in F E V 1 FEV_1 FE V 1 . The reason is practical: P C 20 PC_{20} P C 20 is only comparable between laboratories that use the identical nebulizer, output rate, and inhalation protocol, whereas a cumulative delivered dose is device-independent.
Normal cut-off: a P D 20 > 400 μ g PD_{20} > 400\ \mu g P D 20 > 400 μg of methacholine is considered normal (no clinically significant airway hyperresponsiveness).
Conversion caution: P C 20 PC_{20} P C 20 and P D 20 PD_{20} P D 20 are not interchangeable numbers. A laboratory reporting P C 20 PC_{20} P C 20 must document the nebulizer model, output, and protocol for the value to mean anything outside that lab.
Both appear on exams. NBRC-style items still use the classic P C 20 PC_{20} P C 20 categories below, so know both frameworks and the 20% fall threshold they share.
Clinical Categorization of Airway Hyperresponsiveness ( P C 20 PC_{20} P C 20 )
P C 20 PC_{20} P C 20 Value (mg/mL) Airway Hyperresponsiveness Category Clinical Interpretation
> 16.0 mg/mL > 16.0\text{ mg/mL} > 16.0 mg/mL Normal (Negative Challenge) Excludes active asthma with high negative predictive value
4.0 to 16.0 mg/mL 4.0\text{ to } 16.0\text{ mg/mL} 4.0 to 16.0 mg/mL Borderline AHR Equivocal; clinical correlation required
1.0 to 4.0 mg/mL 1.0\text{ to } 4.0\text{ mg/mL} 1.0 to 4.0 mg/mL Mild AHR Consistent with mild asthma or allergic rhinitis
- 0.25 to 1.0 mg/mL 0.25\text{ to } 1.0\text{ mg/mL} 0.25 to 1.0 mg/mL Moderate AHR Classical active asthma
- < 0.25 mg/mL < 0.25\text{ mg/mL} < 0.25 mg/mL Severe AHR Marked airway hyperreactivity
- Exercise-Induced Bronchospasm (EIB) Testing Protocols
Exercise-Induced Bronchospasm (EIB) is an indirect provocation modality where thermal and osmotic stress (airway cooling and drying caused by high ventilation rates) trigger mast cell degranulation and airway smooth muscle constriction.
Equipment and Environmental Standards
Exercise Modality: Motorized treadmill or cycle ergometer equipped with continuous 12-lead ECG monitoring and pulse oximetry.
Inspired Air Conditions: The patient must breathe dry air containing low absolute humidity ( < 10 mg H 2 O /L < 10\text{ mg } H_2O\text{/L} < 10 mg H 2 O /L ) at a room temperature of 20 ∘ C to 25 ∘ C 20^\circ\text{C to } 25^\circ\text{C} 2 0 ∘ C to 2 5 ∘ C (or cold dry air if evaluating winter athletes).
Workload and Target Ventilation Protocol
Baseline Spirometry: Record repeatable pre-exercise baseline F E V 1 FEV_1 FE V 1 .
Rapid Workload Ramp: The exercise workload must ramp up rapidly within the first 2 to 4 minutes to achieve high target ventilation:
Heart Rate Target: 80 % to 90 % 80\%\text{ to } 90\% 80% to 90% of age-predicted maximum heart rate ( HR max = 220 − age \text{HR}_{\max} = 220 - \text{age} HR m a x = 220 − age ).
Minute Ventilation Target: ≥ 50 % to 60 % \ge 50\%\text{ to } 60\% ≥ 50% to 60% of Maximum Voluntary Ventilation ( M V V MVV M VV ), where estimated M V V = F E V 1 × 35 or 40 MVV = FEV_1 \times 35 \text{ or } 40 M VV = FE V 1 × 35 or 40 .
Sustained Effort: The patient maintains this high target workload for 6 to 8 minutes .
Post-Exercise Spirometry Schedule and EIB Diagnostic Criteria
Testing Intervals: Spirometry ( F E V 1 FEV_1 FE V 1 ) is measured at 5, 10, 15, 20, and 30 minutes post-exercise. (Bronchoconstriction in EIB typically peaks between 5 and 11 minutes post-exercise and spontaneously resolves within 30 to 60 minutes).
EIB Diagnostic Threshold: A ≥ 10 % to 15 % \ge 10\%\text{ to } 15\% ≥ 10% to 15% decline in F E V 1 FEV_1 FE V 1 relative to the pre-exercise baseline is diagnostic of positive Exercise-Induced Bronchospasm. % Fall in F E V 1 = ( F E V 1 , baseline − F E V 1 , lowest post-exercise F E V 1 , baseline ) × 100 \% \text{ Fall in } FEV_1 = \left( \frac{FEV_{1,\text{baseline}} - FEV_{1,\text{lowest post-exercise}}}{FEV_{1,\text{baseline}}} \right) \times 100 % Fall in FE V 1 = ( FE V 1 , baseline FE V 1 , baseline − FE V 1 , lowest post-exercise ) × 100
Laboratory Safety and Reversal Protocol
Bronchial provocation procedures carry inherent risks of severe acute bronchospasm. Technologists must strictly follow facility safety mandates:
Medical Supervision: A qualified physician must be present in the building and immediately reachable during all challenge procedures.
Immediate Bronchodilator Reversal: As soon as a challenge test is deemed positive (or upon completion of the maximum dose/exercise protocol), the technologist must immediately administer an inhaled short-acting beta-agonist ( Albuterol 2.5 mg 2.5\text{ mg} 2.5 mg via nebulizer or 4 puffs via MDI with spacer ).
Post-Test Recovery Monitoring: The patient must remain monitored in the laboratory until F E V 1 FEV_1 FE V 1 recovers to within 10 % 10\% 10% of their initial baseline .
Emergency Resuscitation Readiness: Emergency resuscitation equipment—including supplemental oxygen, airway suction, emergency crash cart with epinephrine and IV bronchodilators—must be physically present inside the testing suite.